文献速递心脑血管急症

急诊就诊时可检测不到的FDA批准高敏肌钙蛋白T浓度用于排除急性心肌梗死

Undetectable Concentrations of a Food and Drug Administration-approved High-sensitivity Cardiac Troponin T Assay to Rule Out Acute Myocardial Infarction at Emergency Department Arrival.
PubMed 文献 · Acad Emerg Med · 2017-08-11
一句话结论真实临床实践中,急诊到达时hsTnT<6 ng/L可高敏感度排除7天AMI,但对MACE敏感度不可接受,单次肌钙蛋白排除策略仅应在结构化风险评估背景下使用。

这项回顾性研究纳入四家城市急诊科连续就诊的疑似心源性胸痛患者,排除ST段抬高型AMI、心脏骤停或肾功能异常者,共7130例。7天、30天、90天AMI发生率分别为5.8%、6.0%、6.2%。急诊到达时hsTnT检测限(3 ng/L)排除7天AMI的敏感度100%、NPV 100%,排除15.5%患者;检测下限(5 ng/L)排除33.6%患者,敏感度99.8%、NPV 99.95%;定量下限(FDA批准的可报告下限,6 ng/L)排除42.2%患者,敏感度99.8%、NPV 99.95%。对7天MACE,<3、<5、<6 ng/L的敏感度分别为99.6%、97.4%、96.6%,NPV分别为99.8%、99.5%、99.4%。在3549例接受连续肌钙蛋白检测的高危亚组中,3 ng/L排除9.6%患者(敏感度100%、NPV 100%),5 ng/L排除23.3%患者(敏感度99.7%、NPV 99.9%),6 ng/L排除29.8%患者(敏感度99.7%、NPV 99.9%);该亚组对7天MACE的敏感度分别为99.8%、97.4%、96.6%,NPV分别为99.7%、98.5%、98.4%。结论认为,真实临床条件下急诊到达时hsTnT<6 ng/L可高敏感度、高NPV排除AMI,但对MACE敏感度不可接受,单次肌钙蛋白排除策略仅应在结构化风险评估背景下使用。

要点

  • 急诊到达时hsTnT<6 ng/L(FDA批准的可报告下限)排除7天AMI的敏感度99.8%、NPV 99.95%,可排除42.2%的患者。
  • hsTnT<5 ng/L排除7天AMI的敏感度99.8%、NPV 99.95%,可排除33.6%的患者;3 ng/L排除15.5%的患者,敏感度100%、NPV 100%。
  • 对7天MACE,<3、<5、<6 ng/L的敏感度分别为99.6%、97.4%、96.6%,NPV分别为99.8%、99.5%、99.4%,作者认为敏感度不可接受。
  • 在3549例接受连续肌钙蛋白检测的高危亚组中,6 ng/L排除7天AMI的敏感度99.7%、NPV 99.9%,可排除29.8%的患者。
  • 作者认为单次肌钙蛋白排除策略仅应在结构化风险评估背景下使用。

适用人群与场景

  • 四家城市急诊科连续就诊的疑似心源性胸痛患者。
  • 排除ST段抬高型AMI、心脏骤停或肾功能异常者。
  • 高危亚组为3549例接受连续肌钙蛋白检测的患者。

研究设计与关键结果

  • 回顾性研究,纳入四家城市急诊科7130例疑似心源性胸痛患者,排除ST段抬高型AMI、心脏骤停或肾功能异常者。
  • 7天、30天、90天AMI发生率分别为5.8%、6.0%、6.2%。
  • 急诊到达时hsTnT 3 ng/L排除7天AMI的敏感度100%、NPV 100%,排除15.5%的患者。
  • hsTnT 5 ng/L排除7天AMI的敏感度99.8%、NPV 99.95%,排除33.6%的患者。
  • hsTnT 6 ng/L排除7天AMI的敏感度99.8%、NPV 99.95%,排除42.2%的患者。
  • 对7天MACE,<3、<5、<6 ng/L的敏感度分别为99.6%、97.4%、96.6%,NPV分别为99.8%、99.5%、99.4%。
  • 在3549例高危亚组中,3 ng/L排除7天AMI的敏感度100%、NPV 100%,排除9.6%的患者;5 ng/L排除23.3%的患者,敏感度99.7%、NPV 99.9%;6 ng/L排除29.8%的患者,敏感度99.7%、NPV 99.9%。
  • 高危亚组对7天MACE的敏感度:<3 ng/L为99.8%、<5 ng/L为97.4%、<6 ng/L为96.6%;NPV分别为99.7%、98.5%、98.4%。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,真实临床条件下急诊到达时hsTnT<6 ng/L可高敏感度、高NPV排除AMI。
  • 作者认为,hsTnT对MACE的敏感度不可接受,单次肌钙蛋白排除策略仅应在结构化风险评估背景下使用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The objective of this study was to quantify the sensitivity of very low concentrations of high-sensitivity cardiac troponin T (hsTnT) at ED arrival for acute myocardial infarction (AMI) in a large cohort of chest pain patients evaluated in real-world clinical practice.

METHODS: This retrospective study included consecutive ED patients with suspected cardiac chest pain evaluated in four urban EDs, excluding those with ST-elevation AMI, cardiac arrest or abnormal kidney function. The primary outcomes were AMI at 7, 30, and 90 days. Secondary outcomes included major adverse cardiac events (MACE; all-cause mortality, AMI, and revascularization) and the individual MACE components. Test characteristics were calculated for hsTnT values from 3 to 200 ng/L .

RESULTS: A total of 7,130 patients met inclusion criteria. AMI incidences at 7, 30, and 90 days were 5.8, 6.0, and 6.2%. When the hsTnT assay was performed at ED arrival, the limit of blank of the assay (3 ng/L) ruled out 7-day AMI in 15.5% of patients with 100% sensitivity and negative predictive value (NPV). The limit of detection of the assay (5 ng/L) ruled out AMI in 33.6% of patients with 99.8% sensitivity and 99.95% NPV for 7-day AMI. The limit of quantification (the Food and Drug Administration [FDA]-approved cutoff for lower the reportable limit) of 6 ng/L ruled out AMI in 42.2% of patients with 99.8% sensitivity and 99.95% NPV. The sensitivities of the cutoffs of <3, <5, and <6 ng/L for 7-day MACE were 99.6, 97.4, and 96.6%, respectively. The NPVs of the cutoffs of <3, <5, and <6 ng/L for 7-day MACE were 99.8, 99.5, and 99.4%, respectively. A secondary analysis was performed in a subgroup of 3,549 higher-risk patients who underwent serial troponin testing. In this subgroup, a cutoff of 3 ng/L ruled out 7-day AMI in 9.6% of patients with 100% sensitivity and NPV, a cutoff of 5 ng/L ruled out 7-day AMI in 23.3% of patients with 99.7% sensitivity and 99.9% NPV, and a cutoff of 6 ng/L ruled out 7-day AMI in 29.8% of patients with 99.7 and 99.9% NPV. In the higher-risk subgroup, the sensitivities of cutoffs of <3, <5, and <6 ng/L for 7-day MACE were 99.8, 97.4, and 96.6%, respectively. In this higher-risk subgroup, the NPV of cutoffs of <3, <5, and <6 ng/L for 7-day MACE were 99.7, 98.5, and 98.4%, respectively.

CONCLUSIONS: When used in real-world clinical practice conditions, hsTnT concentrations < 6 ng/L (below the lower reportable limit for an FDA-approved assay) at the time of ED arrival can rule out AMI with very high sensitivity and NPV. The sensitivity for MACE is unacceptably low, and thus a single-troponin rule-out strategy should only be used in the context of a structured risk evaluation.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. McRae AD, Innes G, Graham M, et al. Undetectable Concentrations of a Food and Drug Administration-approved High-sensitivity Cardiac Troponin T Assay to Rule Out Acute Myocardial Infarction at Emergency Department Arrival. Acad Emerg Med. 2017. PMID: 28544100. doi:10.1111/acem.13229

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。